RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재

      Evaluation of Seroprevalence of SARS-CoV-2 IgG in Healthcare Workers in a Tertiary Hospital in Seoul

      한글로보기

      https://www.riss.kr/link?id=A107648384

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Healthcare workers (HCWs) may be at high risk for exposure to the severe acute respiratorysyndrome coronavirus 2 (SARS-CoV-2) because of their frequent contact with patients or thedirect handling of respiratory samples. We investigated the seroprevalence of SARS-CoV-2IgG in HCWs in Seoul compared to those in coronavirus disease (COVID-19) patients andcommunity-based individuals to evaluate the antibody response. A total of 358 samples from348 individuals (155 HCWs, 7 COVID-19 patients, and 186 community-based individuals) werecollected from April to November 2020. SARS-CoV-2 IgG was detected in 1 of 155 HCWs (1of 46 HCWs with direct contact), 7 of 7 COVID-19 patients, and none of the 186 community based individuals (95% CI: 0.6%, 0.1 - 3.6%; 100%, 64.5 - 100%; 0.0%, 0.0 - 2.0%, respectively).
      The single HCW with a positive result showed 2.32 signal-to-cutoff (S/C) and 2.31 S/C at a3-week interval. Therefore, it was assumed to be a false positive due to autoantibody ormedication. The positive samples from 7 patients had a median of 3.79 S/C (range 1.72 - 6.54).
      The seroprevalence of SARS-CoV-2 IgG in HCWs was very low. The current infection controlstandard seems to be effective in protecting HCWs from COVID-19.
      번역하기

      Healthcare workers (HCWs) may be at high risk for exposure to the severe acute respiratorysyndrome coronavirus 2 (SARS-CoV-2) because of their frequent contact with patients or thedirect handling of respiratory samples. We investigated the seroprevale...

      Healthcare workers (HCWs) may be at high risk for exposure to the severe acute respiratorysyndrome coronavirus 2 (SARS-CoV-2) because of their frequent contact with patients or thedirect handling of respiratory samples. We investigated the seroprevalence of SARS-CoV-2IgG in HCWs in Seoul compared to those in coronavirus disease (COVID-19) patients andcommunity-based individuals to evaluate the antibody response. A total of 358 samples from348 individuals (155 HCWs, 7 COVID-19 patients, and 186 community-based individuals) werecollected from April to November 2020. SARS-CoV-2 IgG was detected in 1 of 155 HCWs (1of 46 HCWs with direct contact), 7 of 7 COVID-19 patients, and none of the 186 community based individuals (95% CI: 0.6%, 0.1 - 3.6%; 100%, 64.5 - 100%; 0.0%, 0.0 - 2.0%, respectively).
      The single HCW with a positive result showed 2.32 signal-to-cutoff (S/C) and 2.31 S/C at a3-week interval. Therefore, it was assumed to be a false positive due to autoantibody ormedication. The positive samples from 7 patients had a median of 3.79 S/C (range 1.72 - 6.54).
      The seroprevalence of SARS-CoV-2 IgG in HCWs was very low. The current infection controlstandard seems to be effective in protecting HCWs from COVID-19.

      더보기

      참고문헌 (Reference)

      1 Theel ES, "The role of antibody testing for SARS-CoV-2 : is there one" 58 : e00797-, 2020

      2 Maxwell LJ, "TNF-alpha inhibitors for ankylosing spondylitis" 18 : CD005468-, 2015

      3 Galanis P, "Seroprevalence of SARS-CoV-2antibodies and associated factors in health care workers : a systematic review and metaanalysis" (S0195-6701) : 30522-, 2020

      4 노지윤, "Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea" 대한의학회 35 (35): 1-6, 2020

      5 Jääskeläinen AJ, "Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation" 129 : 104512-, 2020

      6 Chen SY, "Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan" 9 : 2157-2168, 2020

      7 Korea Disease Control and Prevention Agency (KDCA), "Management guidelines for coronavirus disease-19. Version 9"

      8 Naaber P, "Evaluation of SARSCoV-2 IgG antibody response in PCR positive patients : comparison of nine tests in relation to clinical data" 15 : e0237548-, 2020

      9 Manalac J, "Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and Euroimmune ELISA IgG/IgA assays in a clinical lab" 510 : 687-690, 2020

      10 WHO, "Coronavirus disease (COVID-19) pandemic"

      1 Theel ES, "The role of antibody testing for SARS-CoV-2 : is there one" 58 : e00797-, 2020

      2 Maxwell LJ, "TNF-alpha inhibitors for ankylosing spondylitis" 18 : CD005468-, 2015

      3 Galanis P, "Seroprevalence of SARS-CoV-2antibodies and associated factors in health care workers : a systematic review and metaanalysis" (S0195-6701) : 30522-, 2020

      4 노지윤, "Seroprevalence of Anti-SARS-CoV-2 Antibodies among Outpatients in Southwestern Seoul, Korea" 대한의학회 35 (35): 1-6, 2020

      5 Jääskeläinen AJ, "Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation" 129 : 104512-, 2020

      6 Chen SY, "Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan" 9 : 2157-2168, 2020

      7 Korea Disease Control and Prevention Agency (KDCA), "Management guidelines for coronavirus disease-19. Version 9"

      8 Naaber P, "Evaluation of SARSCoV-2 IgG antibody response in PCR positive patients : comparison of nine tests in relation to clinical data" 15 : e0237548-, 2020

      9 Manalac J, "Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and Euroimmune ELISA IgG/IgA assays in a clinical lab" 510 : 687-690, 2020

      10 WHO, "Coronavirus disease (COVID-19) pandemic"

      11 Korea Disease Control and Prevention Agency (KDCA), "Coronavirus disease (COVID-19)"

      12 Pearce N, "Comparisons between countries are essential for the control of COVID-19" 47 : 1059-1062, 2020

      13 Yoo JY, "Comparative analysis of COVID-19 guidelines from six countries: a qualitative study on the US, China, South Korea, the UK, Brazil, and Haiti" 20 : 1853-, 2020

      14 Hu B, "Characteristics of SARS-CoV-2 and COVID-19" 6 : 1-14, 2020

      15 Elslande JV, "Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs" 26 : 1557e1-1557e7, 2020

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 재인증평가 신청대상 (재인증)
      2020-01-01 평가 등재학술지 선정 (재인증) KCI등재
      2019-12-01 평가 등재후보로 하락 (계속평가) KCI등재후보
      2016-01-01 평가 등재학술지 유지 (계속평가) KCI등재
      2013-03-11 학술지명변경 한글명 : 대한임상미생물학회지 -> Annals of Clinical Microbiology
      외국어명 : Korean Journal of Clinical Microbiology -> Annals of Clinical Microbiology
      KCI등재
      2012-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2009-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2008-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2007-01-01 평가 등재후보학술지 유지 () KCI등재후보
      2005-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 0.19 0.19 0.26
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.22 0.2 0.651 0
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼